District Court Holds Pall in Contempt in Patent Litigation With Mykrolis

Mykrolis Corporation (NYSE: MYK) reported today that the United States District Court for the
District of Massachusetts has held Pall Corporation (NYSE: PLL) in contempt of
court for the violation of a preliminary injunction to discontinue the sale of certain fluid separation devices to its customers. The preliminary injunction, which was issued on April 30, 2004, was dissolved in the Court's ruling. The Court confirmed, however, that Mykrolis is entitled to proceed to trial on its infringement claims against Pall.

The ruling requires Pall to disgorge all profits earned from the sale of its PhotoKleen EZD-2 Filter Assembly products and colorable versions from the date the preliminary injunction was issued through January 12, 2005. In addition, Pall was ordered to reimburse Mykrolis for certain of its attorney's fees associated with the contempt and related proceedings.

Mykrolis filed its law suit in March of 2003 charging Pall with infringing two of its U.S. patents related to technology used in semiconductor manufacturing for point-of-use photochemical dispense and filtration of photoresists and solvents.

Peter W. Walcott, vice president and general counsel for Mykrolis, commented, "We are pleased that the Court sanctioned Pall for its violation of the preliminary injunction. However, we are disappointed that the Court chose to dissolve the preliminary injunction, and we are evaluating the Court's decision to determine our next steps, which may include appeal."

Mykrolis Forward looking Statement Disclaimer

The matters discussed herein, as well as in future oral and written statements by management of Mykrolis Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking
statements. When used herein or in such statements, the words "anticipate", "believe", "estimate", "expect", "hope", "may", "will", "should" or the
negative thereof and similar expressions as they relate to Mykrolis, its business or its management are intended to identify such forward-looking statements. Potential risks and uncertainties that could affect Mykrolis's future operating results include, without limitation, the risk that a sustained industry recovery may be weaker and/or shorter than past recoveries,
our inability to meet increasing demands for our products from our key customers; increased competition in our industry resulting in downward pressure on prices and reduced margins, as well as those risks described under the headings "Risks Relating to our Business and Industry", "Risks Related to the Securities Markets and Ownership of Our Securities," and "Risks Related to our Separation from Millipore" in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form
10-K for the fiscal year ended December 31, 2003 as well as those risks identified in our other reports and filings with the Securities and Exchange Commission.

Contacts:
Bertrand Loy, Chief Financial Officer
Steve Cantor, Director of Investor Relations and Corporate Communications
Tel#: 978-436-6500
Email: investor_relations@mykrolis.com